Cryo-Cell International (NYSEAMERICAN:CCEL) Releases Quarterly Earnings Results

Cryo-Cell International (NYSEAMERICAN:CCEL) announced its quarterly earnings data on Monday. The company reported $0.07 earnings per share (EPS) for the quarter, reports. The business had revenue of $7.85 million for the quarter. Cryo-Cell International had a negative return on equity of 64.31% and a negative net margin of 31.02%.

Cryo-Cell International Stock Up 9.2 %

Shares of NYSEAMERICAN CCEL traded up $0.62 during mid-day trading on Thursday, hitting $7.37. The company had a trading volume of 21,548 shares, compared to its average volume of 9,709. The stock has a market cap of $59.70 million, a P/E ratio of -5.85 and a beta of 0.45. Cryo-Cell International has a 1-year low of $3.62 and a 1-year high of $8.15. The business’s 50-day moving average price is $5.69.

Institutional Trading of Cryo-Cell International

Several hedge funds have recently modified their holdings of CCEL. Rowlandmiller & PARTNERS.ADV purchased a new position in Cryo-Cell International in the first quarter valued at $108,000. Cerity Partners LLC purchased a new position in Cryo-Cell International in the fourth quarter valued at $83,000. Northern Trust Corp purchased a new position in Cryo-Cell International in the fourth quarter valued at $151,000. Finally, Vanguard Group Inc. increased its holdings in Cryo-Cell International by 13.7% in the third quarter. Vanguard Group Inc. now owns 83,883 shares of the company’s stock valued at $441,000 after buying an additional 10,095 shares during the last quarter. 10.44% of the stock is currently owned by institutional investors and hedge funds.

About Cryo-Cell International

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.